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Abstract
Aim This article takes a closer look at the decision-making
process to recommend a new vaccine in the light of the
Finnish experience.
Subject and methods The criteria for evidence-based
knowledge are examined in order to consider how public
health decision-making in the area of immunisation evolves
over time and from one context to the other on the basis of
three of the more recent childhood vaccines (Haemophilus
influenzae type b (Hib), seven-valent pneumococcal conjugate
(PCV-7), and Human Papilloma Virus (HPV)).
Results In the case of Hib vaccine, epidemiological
research concerning both direct and indirect population
protection was the driving force for implementation. By
contrast, PCV-7 universal vaccination was not implemented
on the basis of unfavourable cost-effectiveness evaluation.
However, as this evaluation took place very early on, the
cost-effectiveness analysis did not consider any indirect
herd effects. Regarding the HPV vaccine, it is at present
considered that cervical cancer will be better prevented by
enhancing the already successful PAP smear screening
programme.
Conclusion Surveillance and research are valuable tools for
modern vaccine programme design. Market forces and
advocacy groups strongly drive the development and
implementation of new vaccines, meaning that impartial
and evidence-based decision-making is essential to vaccine
introduction into national programmes. At the same time,
economic analyses are occupying an increasingly important
place in this decision-making. Vaccine costs are not
necessarily compared to government expenditure on illness
and disease. From a moral point of view, it should not be
forgotten that children ought to have the right to best
available health.
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Introduction
National vaccination programmes in European Union
member states vary considerably regarding antigenic
composition and schedule as Lopalco (Lopalco, 2008) and
Schmitt (Schmitt et al. 2003) have already pointed out.
There are several explanations for this. Historical reasons
combine with reasons related to the country’s specific
health-care delivery system and funding mechanisms; these,
in turn, are influenced by current common knowledge of
vaccinology arising from both national and international
evidence and scientific reports. There are major variations
on how such knowledge and evidence are taken into
consideration and used in the context of programme design
and decision-making. In Finland, national vaccination
programme-related research and surveillance are co-ordinated
within the national public health system and form a firm
platform on which vaccine programme-related decisions are
made (Fig. 1).
Ideally, those in charge of developing a national
vaccination programme need to think of the right questions
to ask and communicate them to those in charge of and
financing research and surveillance.
J Public Health (2008) 16:275–280
DOI 10.1007/s10389-008-0204-y





It is essential to choose the right methodology when
wishing to come up with programmatically useful answers.
Well set up and sufficiently sensitive surveillance systems
with sufficiently specific case definitions along with
targeted epidemiological studies shed light on whether the
disease can be considered a public health problem. Vaccine
immunology studies guide in finding optimal doses and
schedules provided serological correlates of protection
exist; they also alert to possible interferences if several
vaccines are combined or given simultaneously. They also
give an understanding on the reactogenicity of the product.
Vaccine efficacy trials are usually required for regulatory
and licensure purposes. Vaccine effectiveness studies
thereafter will provide answers as to whether the disease
actually is vaccine preventable in the intended target
groups. Vaccine safety is thoroughly addressed in clinical
trials for licensure. However, rare adverse events are often
identified only after a large number of doses has been
administered, i.e., subsequent to widespread use of the
vaccine. Thus, reports on adverse events and record linkage
studies impart additional important safety knowledge. The
need to know well in advance the impact of different
vaccination scenarios has promoted the development and
use of advanced tools of mathematical modelling. Simula-
tion models can provide insights in silica as to whether
wide-scale vaccination could have adverse and/or positive
indirect effects on the population level in the long run. An
increasingly important line of modelling is provided by
health economics when considering whether vaccination
could be cost-effective in a given setting.
The key questions a vaccine programme designer needs
to ask are:
Is the disease a public health problem?
Is the disease vaccine preventable?
How does the vaccine work?
Is the vaccine safe?
Could wide-scale vaccinations have adverse or positive
indirect effects on the population level?
Would vaccination be cost-effective?
Research driving vaccine implementation–the example
of the Hib vaccine
In Finland, vaccine research has been an essential part of
programme design for decades. The development of a
Haemophilus influenzae type b (Hib) conjugate vaccine
serves as a good demonstration case. Studies and clinical
trials were carried out in Finland as early as in the 1980s–
1990s (Eskola et al. 1992a, b). The baseline surveillance
study among children under 5 years of age identified the
incidence of Hib disease (52/100,000) as well as its clinical
spectrum. The majority of cases presented as meningitis
and epiglottitis (Takala et al. 1989). The baseline study was
utilised to fine-tune the laboratory infrastructure required to
initiate a nationwide phase III individual randomised
controlled trial, which eventually demonstrated not only
the high direct clinical efficacy of the diphtheria toxoid
conjugated Hib vaccine (Eskola et al. 1990), but also the
indirect protective impact of the vaccine, a ground-breaking
observation (Eskola et al. 1996) (Fig. 2). The latter property
of the vaccine was due to the reduction of the oropharyn-
geal carriage of the bacterium (Takala et al. 1989) and was
soon evident given the decrease in disease incidence among
those not vaccinated. In conjunction with the efficacy trial,
several phase II immunogenicity studies were conducted in
order to better understand the immunological properties and
functional mechanisms of the various Hib vaccines.
In 1993, after the completion of the series of efficacy
studies during which most Finnish infants had received Hib
vaccine according to age, the Hib vaccine was introduced
into the national immunisation programme, i.e., given to all
children in Finland from 3 months of age onwards. This
decision was made in the absence of any formal cost-
efficacy calculations and without major disputes among
stakeholders.
A clinical trial did not secure implementation
into the programme–the example of pneumococcal
conjugate vaccine
The enhanced surveillance system of invasive childhood
diseases established for carrying out the Hib vaccine studies
provided a firm network and basis of national knowledge on
other causative bacterial agents among children (Saarinen et
al. 1995). The gate keeping and development of the
notification system were transferred from the Medical Board
to the National Public Health Institute (Kansanterveyslaitos,
KTL), which was charged with establishing a computer-
based national communicable disease registry. For pneumo-
coccus, special surveillance studies aimed at understanding
pneumonia (Jokinen et al. 1993) and acute otitis media (Kilpi








Fig. 1 Protecting the population with vaccination. The relation of
surveillance, research, decision-making, and implementation, and the
role of the National Public Health Institute (KTL)
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surveillance system. It became evident that with the
relatively low incidence rates of invasive pneumococcal
disease among children (Eskola et al. 1992a, b), a phase III
clinical trial with the endpoint of invasive pneumococcal
disease would be an immense nationwide undertaking.
Instead, the researchers agreed on a smaller pre-licensure
trial with originally three new pneumococcal conjugate
vaccines to be carried out to address a clinically less severe
endpoint: otitis media. In Finland otitis media actually
caused a much greater public health disease burden. This
trial established the mean serotype-specific efficacy of 57%
of the two candidate vaccines licensed (Eskola et al. 2001;
Kilpi et al. 2003) and also provided important information on
the disease burden itself. After the trial, however, seven-
valent pneumococcal conjugate vaccine (PCV-7) did not
make it to the national programme. Why not? How did this
happen? Most professionals and lay persons alike were
perplexed. What had changed between the 1990s and 2000?
From expert advice to policy formation-What changed
between the 1990s and 2000?
At the turn of the present century several new paediatric
vaccines became available on the market. Of these, both the
rotavirus vaccine and pneumococcal conjugates were
studied in Finland as part of the manufacturers phase III
licensure trials (Eskola et al. 2001; Kilpi et al. 2005;
Joensuu et al. 1997). It was no longer self-evident,
however, that all these efficacious vaccines could be
adopted by the national programme without going through
a process of formal consideration, completely detached
from the investigators’ own interests. Also, the higher cost
of the vaccines called for a thorough economic analysis. In
face of the increasing public and professional demand that
health policies and guidelines of all kinds be based as much
as possible on scientifically sound evidence, this without
doubt also applied to the introduction of any new vaccine.
In 2000, a national advisory committee for vaccination
(Kansallinen rokotusasiantuntijaryhmä, KRAR) was formed
that commissioned vaccine-specific expert groups to help
evaluate the scientific evidence on the basis of which the
new vaccine was to be introduced (Fig. 3) (Rapola 2007).
To standardise these expert evaluations, KRAR agreed on a
“four-step” approach. In order to be considered for
financing from the national health budget, the following
four criteria had to be met:
(1) Public health benefit, i.e., there should be a considerable
disease burden, and vaccination should be expected to
alleviate this burden;
(2) Vaccine safety on the individual level, i.e., the risks of
vaccination to an individual should be minimal and
outweighed by the expected health benefits;
(3) Vaccine safety on the population level, i.e., wide-scale
vaccination should not have major adverse effects on
the population in short or long term;













Fig. 3 Decision-making struc-
tures of the National Immunisa-
tion Programme in Finland at


















Fig. 2 The impact of Hib vaccination on the vaccinated age groups (i.e.,
direct effect) and those beyond the target age group (i.e., the so-called
indirect herd effect). According to Eskola et al. (Rev Med Microbiol
1996; 7: 231–241) and the National Infectious Disease Register
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(4) Cost-effectiveness, i.e., the intervention should be
sufficiently cost-effective from the societal point of
view as the universal vaccination programme is
completely shouldered by the Finnish government.
Despite the licensure trials having been carried out in the
country, PCV-7 was scrutinised according to the “four-step”
approach. For the evaluation task, the vaccine expert group
accessed local disease burden data via the national
communicable disease registry and combined it with trial-
related data on both burden and efficacy (Table 1). Based
on the 2000 costing figures, in an annual birth cohort of
55,000 infants, the cost effectiveness analysis indicated
when considering the direct effects alone, investing 12.0
million € would save annually 6.3 million € in medical and
2.0 million € in productivity and other costs. Therefore,
investing 1 million € in a vaccination programme would
return 0.53 million € in medical costs and 0.70 million € in
societal costs. In the base case, vaccination would cost
society 134,986 € per life year saved (LYS). To achieve cost
savings from a health-care provider (societal) perspective,
the price of PCV-7 should be 50% (70%) of the price used in
the base case. In other words, PCV-7 did not avert enough
cases and deaths in comparison to the predicted costs when
given as a four-dose schedule, assuming similar vaccine
efficacy point prevalence values as in the US trials for
invasive disease and otitis complications and in the Finnish
trials for acute otitis media-related events (Salo et al. 2005).
The cost-effectiveness analysis at that time did not take
into consideration the possibility of the serotype replace-
ment phenomenon or the indirect herd protection of PCV-7
in averting disease in the non-vaccinated age groups
(Anonymous, 2005) as very little data beyond the proof
of reduction of upper respiratory carriage of pneumococcus
(Dagan et al. 1996) was then available. As a result of an
early, and in retrospect a very conservative evaluation,
PCV-7 was not introduced into the Finnish immunisation
programme on the universal level; it was recommended to be
Table 1 Pneumococcal disease burden in children <5 years of age in Finland and episodes assumed to be averted by vaccination with the seven-












89.1 Black et al. 2000 60
Pneumonia 8,000 Jokinen et al. 1993 17.7 Black et al. 2000 1,400
Acute otitis media 250,000 Eskola et al. 2001 6.0 Eskola et al. 2001 15,000
Otologic surgery procedures 15,000 National Registry 20.3 Black et al. 2000 3,000
Death 1 Klements et al. 2004 NA NA 0.9
NA = not available
Table 2 The recent evaluations and changes made in the Finnish national immunisation programme since 2000-as suggested by the National
Advisory Committee for Vaccines (KRAR)
Year Vaccine Type of change Target group Evaluation included
formal economic analysis
Reference
2001 Pneumococcal conjugate Introduction To risk groups <5 years only Yes Salo et al. 2005
2002 Influenza Introduction Elderly >65 No CR
2003 DTaP/dtap Introduction 6 year olds No CR
2005 DTaP-IPV-Hib Introduction All infants at 3, 5, 12 months No CR
2006 Tick Borne Encephalitis 5-year campaign >7 years old living permanently on Åland Yes CR
2006 Bacillus Calmette Guerin Restriction Only to risk group newborns* Yes CR
2007 Influenza Introduction 3–35-month-old children Yes Salo et al. 2006
2007 Rotavirus Introduction Before 4 months Yes Salo et al. 2007
2008 Pneumococcal conjugate Introduction TBD Yes NA
2008 Varicella Introduction TBD Yes; ongoing NA
2009 Human Papilloma Virus Introduction TBD Yes; ongoing NA
*Previously was given to all newborns
CR = Expert Committee Report (in Finnish language, available from the KTL website www.ktl.fi)
NA = not yet available
TBD = to be decided
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given to risk group children only (Nohynek et al. 2005). A
new evaluation including potential herd effects and replace-
ment phenomenon, and calculating impact in quality-
adjusted life years (QALY) in addition to LYS, is nearing
completion, after which the earlier negative decision will
soon be revisited.
What will happen in the future–the example of Human
Papilloma Virus-vaccine in preventing cervical cancer
Similarly to the PCV-7 evaluation, several other vaccine
antigens have been considered for introduction, reduction
or campaign for a limited time period. Table 2 summarises
the recent changes in the Finnish national immunisation
programme and ongoing evaluations initiated by KRAR
since 2000. Since the first PCV-7 evaluation, three other
vaccines have gone through the critical four-step process.
The cost effectiveness evaluation for all these three, i.e.,
TBE, influenza and rota vaccines, utilising local disease
burden and health-care costing data has been favourable
(Salo et al. 2006, 2007), unlike in many other European
countries, and accordingly, they have been or will be
introduced into the national programme.
It goes without saying that evidence-based decision
making is here to stay. From 2001 to 2005, the annual
national budget for vaccines doubled from 5 to 10 million
euros. With all the expected changes (Table 2, i.e.,
introduction of influenza, rota, varicella, pneumococcus
and human papilloma virus vaccines), the budget would
increase more than four-fold, up to 43 million euros.
Whether the four-step approach is extensive and fair
enough is a matter of present debate. Market forces strongly
drive new childhood vaccines, keen on having them used
by as many children as possible. When professionals are
not in full agreement and decision-making processes slow
down, the pharmaceutical industry targets common people
raising disease and problem-specific awareness with their
advertising campaigns and approaches of opinion leaders
and politicians. Sometimes these initiatives can be quite
imaginative, taking advantage of parental feelings of guilt
and general concerns of health. On the other hand one
should not forget that children should have the right to
optimal health as declared by the United Nations Special
Conference for Children in 2002.
An example of a heated debate on a new vaccine
introduction is provided by the present situation of the
Human Papilloma Virus (HPV) vaccines in Finland.
According to the Finnish Cancer Registry, approximately
150 new cervical cancer cases are detected annually, mostly
in women above 25 years of age. Simultaneously 60 deaths
are caused by cervical cancer, 90% of which occur in
women over 50 years of age. According to the present data,
vaccinating girls above 12 years could reduce cervical
cancer incidence after 20 years and deaths after 40 years of
follow-up. With the experience of the rapid, world-record
reduction of cervical cancer screening in Finland since the
introduction of the PAP smear screening programme in year
1953 (Fig. 4), the present thinking on the national level is to
intensify the already highly successful PAP smear screening.
Intensifying screening especially in the younger age groups
would most likely have a positive impact on these morbidity
and mortality figures much faster than introducing an HPV
vaccine, given the fact that the reported overall vaccine
efficacy figures of HPV on cervical precancerous lesions





















Fig. 4 Age-standardised incidence and mortality of cervical cancer in
Finland since 1953










6-35 months Influenza, annual
a D = diphtheria, T = tetanus, P = pertussis, polio, Hib = Haemophilus
influenzae type b
bM = measles, M = mumps, R = rubella
c Booster dose, small lettes indicating lower amoint of antigens
The only addition since 2005 is the annual influenza vaccination of
children 6–35 months of age. BCG, HBV and tick-born encephalitis
vaccines are given to risk group children only. Vaccines to prevent
from foreign travel-related infections are not covered by the universal
vaccination programme (http://www.ktl.fi).
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caused by all HP viruses is only 27% in non-naïve
individuals and that introduction of a vaccine would not
bring about savings in the form of reducing screening costs.
A multidisciplinary HPV expert group will be called upon to
look into detail in these issues and suggest actions to be
taken by the government and various stakeholders.
There are increasingly critical voices questioning to what
extent economic analyses should be given weight in the
decision-making processes. One of the arguments posed is a
moral one: children should have the right to the best
available health regardless of price. As a consequence,
access to new vaccines is seen as part of the rights of a
child that a nation should fulfil (Feudtner C and Marcuse E,
2001). Another opposing view is that rather than comparing
present vaccination costs to previous ones, it would be more
judicious to compare vaccination to other health interven-
tions, especially those targeted to sick people. In 2005 the
Finnish government paid approximately 200 € for vaccines
per each Finnish child up to 18 years of age (Table 3). This is
in striking contrast to the funds spent by the state to cover
medical expenses linked to diseases. For example, according
the National Health Insurance statistics, in 1 year alone, in
2005, for each of the 9% of Finns officially diagnosed with
hyperlipidemia, the Finnish State paid 95–164 € in order to
cover the costs of related medications (statins) alone. For
such a comparison to be justified and seriously taken into
account while resources are limited, a major shift of
paradigm would need to take place. Are society and health-
care professionals ready for it?
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